EPPIC Net

Active trials:

Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy (EN-21)

EN-21 is a platform protocol conducted within EPPIC-Net investigating pain treatments for adult participants with Painful Diabetic Peripheral Neuropathy. Within this platform protocol, the currently enrolling study is a phase 2, randomized, controlled trial of NRD135S.E1, a novel, non-opioid pain medication. The study is seeking to see if the medication is more effective than placebo in treating painful neuropathy symptoms from diabetes. EN-21 is sponsored by the National Institute of Health (NIH) and Massachusetts General Hospital (MGH). Dr. Mark Williams is the site PI for this trial, with Dr. Annie Philip and Dr. Jennifer Gewandter as Co-Is.

For more information on this study, please visit clinicaltrials.gov. If you are interested in participating, please fill out our interest survey.        

Completed Trials:

EN20-01: A 24-Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects with Moderate to Severe Knee Osteoarthritis Pain.

A Phase 2, randomized, allocation-concealed, multicenter, placebo-controlled, multi-crossover design. The primary objective of this study was to evaluate the safety and efficacy of 300mg.